| Document |
Document Title |
|
WO/2015/067651A1 |
The present application relates to novel substituted uracil derivatives, to a method for the production thereof, to the use thereof either alone or in combination for treating and/or preventing diseases, and to the use thereof for produc...
|
|
WO/2015/064580A1 |
Provided is a sulfonamide derivative represented by general formula (1) [wherein A, B, D, E, R41 and a to h are each as defined in the description], which has a highly selective α4 integrin inhibitory effect, i.e., being less effective ...
|
|
WO/2015/064532A1 |
The purpose of the present invention is to prevent or treat hyperphosphatemia or disease associated with hyperphosphatemia. To fulfill this purpose, a compound having general formula (I), or a pharmaceutically acceptable salt thereof, is...
|
|
WO/2015/060368A1 |
The present invention addresses the problem of providing a compound which has a PDE2A inhibitory action and is useful as an agent for preventing or treating schizophrenia, Alzheimer's disease, etc. The present invention relates to a comp...
|
|
WO/2015/059712A1 |
This invention relates to the preparation of Methyl 2-[2-(6-chloropyrimidin-4- yloxy)phenyl}-3-methoxypropanoate, more economically with non-recyclable or recyclable catalyst, which can be reused without losing its activity, where the sa...
|
|
WO/2015/061074A1 |
There is provided a compound having Formula I In Formula I: R1 - R10 are the same or different and are H, D, alkyl, silyl, aryl, deuterated alkyl, deuterated silyl, or deuterated aryl, where no more than two of R1 - R10 are biphenyl and ...
|
|
WO/2015/059618A1 |
The present disclosure is directed to substituted pyrimidine compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPG...
|
|
WO/2015/058519A1 |
Disclosed in the present invention is a triketone compound which has a structure shown in formula (I). Also disclosed in the present invention is a method for preparing the triketone compound having a structure as shown by formula (I), w...
|
|
WO/2015/060373A1 |
The present invention relates to quinazolinone and isoquinolinone derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.
|
|
WO/2015/057938A1 |
Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
|
|
WO/2015/057629A1 |
The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, ...
|
|
WO/2015/055275A1 |
This invention relates to N-alkyl-N'-poly(oxyalkyl)hexapyrimidine- quaternary ammonium salts of the formulae (la) - (lc) and mixtures thereof in which R1 is C8-C30-alkyl or C8-C30-alkenyl, R2 is hydrogen, C1-C3-alkyl, -COOH or a group se...
|
|
WO/2015/056782A1 |
The purpose of the present invention is to provide a novel compound having ACC2-inhibiting activity and to provide a pharmaceutical composition comprising said compound. A compound indicated by formula (in the formula, R1 indicates a sub...
|
|
WO/2015/056683A1 |
The present invention addresses the problem of providing: a compound exhibiting excellent stability and/or solubility and the like, and further improved FLT3 inhibitory activity; and a pharmaceutical composition. The present invention pr...
|
|
WO/2015/057963A1 |
Provided herein are compounds of Formula I and Formula II useful as FGFR4 inhibitors, as well as methods of use of the same.
|
|
WO/2015/055806A1 |
The present invention provides a system for evaporating a radioactive fluid, a method for the synthesis of a radiolabelled compound including this system, and a cassette for the synthesis of a radiolabelled compound comprising this syste...
|
|
WO/2015/057626A1 |
The present invention comprises compounds of Formula (I): wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease...
|
|
WO/2015/054572A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b...
|
|
WO/2015/054474A1 |
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that in...
|
|
WO/2015/050140A1 |
The present invention provides the following: a compound in which at least the 8-position (or 9-position) of a fluoranthene represented by formula (1) is substituted with a nitrogen atom; an organic electroluminescent element material us...
|
|
WO/2015/046450A1 |
An active light sensitive or radiation sensitive resin composition which is characterized by containing (A) an alkali-soluble resin and (C) a crosslinking agent represented by general formula (1-0).
|
|
WO/2015/048246A1 |
The present disclosure provides tetra-substituted cyclobutane inhibitors of Androgen Receptor Action, and methods of using such inhibitors, for the treatment of hormone-refractory cancers.
|
|
WO/2015/043093A1 |
The present invention discloses a method for preparing 4,6-dichloropyrimidine, comprising the following steps: 1) mixing 4,6-dipyrimidine, phosphorus oxychloride and phosphorus pentachloride, controlling the temperature to be 50-110°C a...
|
|
WO/2015/044075A1 |
The present invention relates to compounds of formula I wherein Y is N or C-R1'; G is a 5 or 6-membered aromatic or heteroaromatic ring containing 0, 1, 2 or 3 heteroatoms, selected from the group consisting of phenyl, pyridinyl with dif...
|
|
WO/2015/046955A1 |
The present disclosure relates to a novel organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure has excellent hole transport ab...
|
|
WO/2015/046916A1 |
The present invention relates to a specific combination of dopant compounds and host compounds. By using a combination of the dopant and host compounds according to the present invention, an organic electroluminescent device has improved...
|
|
WO/2015/046317A1 |
The purpose of the present invention is to provide novel acethylene amide derivatives, i.e., a compound having an antagonistic activity on all of PPARα, PPARβ/δ and PPARγ, a compound having an antagonistic activity on at least one su...
|
|
WO/2015/039348A1 |
The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein n, X, Y, Z, R1, R2, and R3 are as defined herein. The present invention also relates to c...
|
|
WO/2015/039613A1 |
A compound capable of inhibiting kinase activities of BTK and/or JAK3, a pharmaceutical composition, and applications in preparing a medicament. The compound is as represented by structural formula I, where the definitions of the substit...
|
|
WO/2015/042077A1 |
The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is...
|
|
WO/2015/040425A1 |
A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: Y is –CONR1- or optionally substituted arylene or optionally substituted heteroarylene; R1 is H, Cl, F, CH3 or CF3; 10 each R4 is independently H, CH3 or ...
|
|
WO/2015/041148A1 |
A method for manufacturing voriconazole, said method including: a step for converting a compound represented by general formula (1) into a compound represented by general formula (2); a step for converting the compound represented by gen...
|
|
WO/2015/039333A1 |
The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, at...
|
|
WO/2015/039387A1 |
The present invention relates to a compound synthesis method, and specifically relates to a preparation method for 4,6-pyrimidine dihalide-5-acetaldehyde. The preparation method for 4,6-pyrimidine dihalide-5-acetaldehyde comprises: the c...
|
|
WO/2015/036560A1 |
The invention relates to novel heterocyclic substituted 6-(trifluoromethyl)pyrimidine- 4(3H)-one derivatives, to a method for the production thereof, to the use thereof either alone or in combination for the treatment and/or prevention o...
|
|
WO/2015/037548A1 |
An organometallic iridium complex has high emission efficiency and a long lifetime. The iridium complex includes the structure represented by Formula (G1). In the formula, Ar represents a substituted or unsubstituted arylene group having...
|
|
WO/2015/037018A1 |
The present invention provides an industrially advantageous and cost-effective process for preparation of rosuvastatin of formula I or pharmaceutically acceptable salts thereof, [Formula I should be inserted here], via novel intermediate...
|
|
WO/2015/036563A1 |
The invention relates to novel 2,5-disubstituted-6-(trifluoromethyl)pyrimidine-4(3H-one derivates, to a method for the production thereof, to the use thereof either alone or in combination for the treatment and/or prevention of diseases,...
|
|
WO/2015/032192A1 |
Disclosed is a method for preparing an intermediate of azoxystrobin represented by formula (1) and formula (2). The method comprises: in the presence of a catalyst, enabling a compound represented by formula (3) to be in contact with sod...
|
|
WO/2015/030847A1 |
Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B -cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 funct...
|
|
WO/2015/030002A1 |
[Problem] The present invention addresses the problem of providing a method for producing an optically active 5-hydroxy-3-ketoester compound which has a high reaction yield and high stereoselectivity, and is useful as an intermediate for...
|
|
WO/2015/030001A1 |
[Problem] The purpose of the present invention is to provide a method for manufacturing optically active 5-hydroxy-3-ketoesters with high yield and high stereoselectivity that can be used as a pharmaceutical intermediate. The purpose of ...
|
|
WO/2014/096864A9 |
The present subject matter relates generally to compounds having the formula (I): wherein each of X, Y, R1, R2, R3, R4, and n are as defined herein. Compounds of formula (I) may act as inhibitors of the thioredoxin reductase enzyme syste...
|
|
WO/2015/031819A1 |
To study RNA function using small molecules, we designed bioactive, modularly assembled small molecules that target the noncoding expanded RNA repeat that causes myotonic dystrophy type 1 (Dml), r(CUG)exp. Different modular assembly scaf...
|
|
WO/2015/027005A1 |
The present invention relates to a deuterated pyrrolo[2,3-b]pyridinyl compound that is useful for inhibiting Janus kinases. The invention also relates to processes and intermediates useful for preparing such a compound.
|
|
WO/2015/027212A1 |
This invention pertains to diaminopyrimidine compounds having activity as antagonists of P2X purinergic receptors, and to methods for treatment of diseases associated with P2X receptors comprising administering an effective amount of a d...
|
|
WO/2015/026792A1 |
Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating...
|
|
WO/2015/025164A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, formula (I) wherein R1. X, m. R2, Y, R3, Z, n, R4. A and B are as defined in the specification, processes for their preparation, pharm...
|
|
WO/2015/025326A1 |
The present invention provides 3-(4-ethynylphenyl) pyridopyrimidinone compounds of formula A as potential anticancer agents. 3-(4-ethynylphenyl) pyridopyrimidinone compounds have shown promising anticancer activity in various cell lines ...
|
|
WO/2015/025197A1 |
The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of prepa...
|
